EDS_FLU produced higher systemic exposure than Flonase and substantially lower systemic exposure than Flovent 440mcg, indicating that drug deposition is greatly improved with EDS vs. conventional nasal spray.
Based on the pathophysiological and clinical characteristics of N-ERD, anti-IL 5 therapy may be effective in this patient subgroup.
Patients with hereditary angioedema (HAE) on long-term prophylaxis with attenuated androgen (LTP-AA) appeared to have a higher risk for cardiovascular disease but a lower number of neoplasms.
The XTEND-CIU study assessed patients aged ≥12 years for the safety and efficacy of longer-term omalizumab treatment (48 weeks) and helped to better understand drug discontinuation in patients with chronic idiopathic urticaria.
Patients in the study were ≥13 years old, had a <50% of normal functional C1INH level, and a history of at least 4 monthly HAE attacks for at least 3 months.
Analysis indicated that skin attacks were treated more frequently in early self-treaters compared to late treaters.
Systemic reactions (SR) associated with subcutaneous immunotherapy (SCIT) were found to be mild in severity and mainly occurred during the build-up phase of IT.
Hereditary angioedema attacks were included in the pooled analysis if overall severity score reached at least 50mm on a 100mm visual analog scale.
Aspirin-sensitive asthma patients had greater improvements in pulmonary function after treatment with zileuton CR vs. asthma patients without aspirin sensitivity.
The authors analyzed data for 21 patients who had switched from C1INH(IV) for routine HAE prophylaxis to C1INH(SC) for routine prevention as part of the COMPACT trial.
Dr. Taniguchi aimed to describe the pathomechanism of induction of severe airway symptoms in AERD patients and described potential mechanisms of anti-IgE (omalizumab) as a treatment for AERD.
Skin prick tests found that infants with eczema had significantly larger wheal sizes to histamine compared to infants without eczema.
They evaluated dupilumab's effects on smell function with 60 patients with nasal polyps who were refractory to intranasal corticosteroids.
Allergen-specific subcutaneous immunotherapy (SCIT) reduced 5- to 11-year-old children's need for inhaled corticosteroids (ICS) to manage asthma symptoms.
Assessment of predictive factors for systemic allergic reactions (SAR) determined that peanut oral immunotherapy (OIT) is safe in patients with peanut allergy (PA).
Supervised self-injection practice in the clinic to simulate adolescents' use of an epinephrine autoinjector to manage food allergy anaphylaxis offers immediate improvements in patients' comfort levels.
Adding tiotropium Respimat to maintenance therapy of inhaled corticosteroid was found to significantly improve lung function in adolescents and children.
Safety data of long-term treatment with 300IR 5-grass SL tablet indicated that "the most frequent ADRs, generally mild, were reported with decreasing incidences over the years studied and could persist up to 4 months during treatment."
A Fluticasone Propionate Exhalation Delivery System (FLU-EDS) has shown significant improvements in patients diagnosed with Chronic Rhinosinusitis with Nasal Polyps.